-
公开(公告)号:EP3290424A1
公开(公告)日:2018-03-07
申请号:EP16786500.5
申请日:2016-04-27
申请人: Shionogi & Co., Ltd
IPC分类号: C07D498/14 , C07D513/14 , C07D491/22 , C07D471/14 , A61K31/5383 , A61K31/542 , A61K31/53 , A61P31/16
CPC分类号: C07D498/14 , A61K31/53 , A61K31/5383 , A61K31/542 , A61K31/553 , A61K31/675 , A61P31/16 , C07C2601/08 , C07C2601/16 , C07D471/14 , C07D471/20 , C07D491/22 , C07D513/14 , C07D519/00 , C07F7/1804 , C07F9/6561
摘要: The present inventon provides the following compounds having anti-viral activity.
A 1 is CR 1A R 1B , S or O;
A 2 is CR 2A R 2B , S or O;
A 3 is CR 3A R 3B , S or O;
A 4 is CR 4A R 4B , S or O;
the number of hetero atoms among atoms constituting the ring which consists of A 1 , A 2 , A 3 , A 4 , nitrogen atom adjacent to A 1 and carbon atom adjacent to A 1 , is 1 or 2;
R 1A and R 1B are each independently hydrogen, halogen, alkyl, or the like;
R 2A and R 2B are each independently hydrogen, halogen, alkyl, or the like;
R 3A and R 3B are each independently hydrogen, halogen, alkyl, or the like;
R 4A and R 4B are each independently hydrogen, halogen, alkyl, or the like;
R 3A and R 3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle;
X is CH 2 , S or O;
R 1 is each independently halogen, hydroxy, or the like;
m is any integer of 0 to 2; and
n is any integer of 1 to 2.摘要翻译: 本发明提供了具有抗病毒活性的下列化合物。 A1是CR1AR1B,S或O; A2是CR2AR2B,S或O; A3是CR3AR3B,S或O; A4是CR4AR4B,S或O; 构成由A1,A2,A3,A4,与A1相邻的氮原子和与A1相邻的碳原子构成的环的原子中的杂原子数为1或2; R1A和R1B各自独立地为氢,卤素,烷基等; R2A和R2B各自独立地为氢,卤素,烷基等; R3A和R3B各自独立地为氢,卤素,烷基等; R4A和R4B各自独立地为氢,卤素,烷基等; R3A和R3B可以一起形成非芳族碳环或非芳族杂环; X是CH2,S或O; R1各自独立地为卤素,羟基等; m是0至2的任何整数; 并且n是1至2的任何整数。
-
2.
公开(公告)号:EP3498281A1
公开(公告)日:2019-06-19
申请号:EP17839530.7
申请日:2017-08-09
申请人: Shionogi & Co., Ltd.
IPC分类号: A61K31/5383 , A61P31/12 , A61P31/16 , A61P43/00
摘要: The present invention provides a pharmaceutical composition containing the following compound having antiviral action:
P is hydrogen or a group to form a prodrug.-
公开(公告)号:EP4238960A8
公开(公告)日:2023-11-22
申请号:EP21886259.7
申请日:2021-10-27
发明人: OKANO, Azusa , TATENO, Yusuke , NODU, Kouhei , SUZUKI, Shinji , AKIYAMA, Toshiyuki , MATOYAMA, Masaaki , AKAZA, Hiroto , FUKUDA, Takashi
IPC分类号: C07D20060101
摘要: The present invention provides a compound represented by formula (I) :
wherein the dashed line indicates the presence or absence of a bond; R 1 is carboxy or the like; L is substituted or unsubstituted non-aromatic carbocyclyldiyl or the like; R 2 is substituted or unsubstituted alkyl; R 3 is a hydrogen atom or the like; X is =CR X -or =N-; Y is =CR Y - or =N-; U is -CR U = or -N=; V is -CR V = or -N=; W is =CR W - or =N-; Z A is -C= or -N-; Z B is -CR 5 R 6 - or the like; Z C is -CR 7 R 8 - or the like; R X , R Y , R V and R W are each independently a hydrogen atom or the like; R U is a hydrogen atom or the like; R 5 and R 6 are each independently a hydrogen atom or the like; R 7 and R 8 are each independently a hydrogen atom or the like; R 4 is substituted or unsubstituted alkyloxy or the like,
or a pharmaceutically acceptable salt thereof, having an antiviral activity; and a pharmaceutical composition comprising the same.-
公开(公告)号:EP4238960A1
公开(公告)日:2023-09-06
申请号:EP21886259.7
申请日:2021-10-27
发明人: OKANO, Azusa , TATENO, Yusuke , NODU, Kouhei , SUZUKI, Shinji , AKIYAMA, Toshiyuki , MATOYAMA, Masaaki , AKAZA, Hiroto , FUKUDA, Takashi
IPC分类号: C07D20060101
摘要: The present invention provides a compound represented by formula (I) :
wherein the dashed line indicates the presence or absence of a bond; R 1 is carboxy or the like; L is substituted or unsubstituted non-aromatic carbocyclyldiyl or the like; R 2 is substituted or unsubstituted alkyl; R 3 is a hydrogen atom or the like; X is =CR X -or =N-; Y is =CR Y - or =N-; U is -CR U = or -N=; V is -CR V = or -N=; W is =CR W - or =N-; Z A is -C= or -N-; Z B is -CR 5 R 6 - or the like; Z C is -CR 7 R 8 - or the like; R X , R Y , R V and R W are each independently a hydrogen atom or the like; R U is a hydrogen atom or the like; R 5 and R 6 are each independently a hydrogen atom or the like; R 7 and R 8 are each independently a hydrogen atom or the like; R 4 is substituted or unsubstituted alkyloxy or the like,
or a pharmaceutically acceptable salt thereof, having an antiviral activity; and a pharmaceutical composition comprising the same.-
公开(公告)号:EP4424314A2
公开(公告)日:2024-09-04
申请号:EP24172424.4
申请日:2016-04-27
申请人: Shionogi & Co., Ltd
IPC分类号: A61K31/5383
CPC分类号: A61K9/0014 , A61K9/0019 , A61K9/0056 , A61K9/0075 , A61K9/0095 , A61K9/06 , A61K9/1611 , A61K9/1623 , A61K9/2018 , A61K9/2054 , A61K9/485 , A61K9/4858 , A61K9/7038 , A61K47/06 , A61K47/26 , A61P31/00 , A61P31/16 , C07D498/14 , C07F7/1804 , C07F9/6561
摘要: The present inventon provides the following compounds having anti-viral activity.
A1 is CR1A R1B, S or O;
A2 is CR2A R2B, S or O;
A3 is CR3AR3B, S or O;
A4 is CR4AR4B, S or O;
the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A1, is 1 or 2;
R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like;
R3A and R3B are each independently hydrogen, halogen, alkyl, or the like;
R4A and R4B are each independently hydrogen, halogen, alkyl, or the like;
R3A and R3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle;
X is CH2, S or O;
R1 is each independently halogen, hydroxy, or the like;
m is any integer of 0 to 2; and
n is any integer of 1 to 2.-
公开(公告)号:EP4219508A1
公开(公告)日:2023-08-02
申请号:EP23150186.7
申请日:2016-04-27
申请人: Shionogi & Co., Ltd
IPC分类号: C07D498/14 , A61P31/16 , A61K31/5383
摘要: The present inventon provides the following compounds having anti-viral activity.
A 1 is CR 1A R 1B , S or O;
A 2 is CR 2A R 2B , S or O;
A 3 is CR 3A R 3B , S or O;
A 4 is CR 4A R 4B , S or O;
the number of hetero atoms among atoms constituting the ring which consists of A 1 , A 2 , A 3 , A 4 , nitrogen atom adjacent to A 1 and carbon atom adjacent to A 1 , is 1 or 2;
R 1A and R 1B are each independently hydrogen, halogen, alkyl, or the like;
R 2A and R 2B are each independently hydrogen, halogen, alkyl, or the like;
R 3A and R 3B are each independently hydrogen, halogen, alkyl, or the like;
R 4A and R 4B are each independently hydrogen, halogen, alkyl, or the like;
R 3A and R 3B may be taken together to form non-aromatic carbocycle or non-aromatic heterocycle;
X is CH 2 , S or O;
R 1 is each independently halogen, hydroxy, or the like;
m is any integer of 0 to 2; and
n is any integer of 1 to 2.-
公开(公告)号:EP3428170A1
公开(公告)日:2019-01-16
申请号:EP18189193.8
申请日:2016-04-27
申请人: SHIONOGI & CO., LTD
IPC分类号: C07D498/14 , A61P31/16 , A61K31/5383
摘要: The present inventon provides the following compounds having anti-viral activity.
-
8.
公开(公告)号:EP4458348A2
公开(公告)日:2024-11-06
申请号:EP24190015.8
申请日:2017-08-09
申请人: Shionogi & Co., Ltd
IPC分类号: A61K9/06
摘要: The present invention provides a pharmaceutical composition containing the following compound having antiviral action:
P is hydrogen or a group to form a prodrug;
A 1 is CR 1 A R 1 B , S or O;
A 2 is CR 2 A R 2 B , S or O;
A 3 is CR 3 A R 3 B , S or O;
A 4 is each independently CR 4 A R 4 B , S or O;
the number of hetero atoms among atoms constituting the ring which consists of A 1 ,
A 2 , A 3 , A 4 , nitrogen atom adjacent to A 1 and carbon atom adjacent to A 4 , is 1 or 2;
R 1 A and R 1 B are each independently hydrogen, halogen, alkyl, or the like;
R 2 A and R 2 B are each independently hydrogen, halogen, alkyl, or the like;
R 3 A and R 3 B are each independently hydrogen, halogen, alkyl, or the like;
R 4 A and R 4 B are each independently hydrogen, halogen, alkyl, or the like;
R 3 A and R 3 B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle;
R 1 is fluorine;
m is any integer of 1 to 2; and
n is any integer of 1 to 2.-
公开(公告)号:EP3192794A1
公开(公告)日:2017-07-19
申请号:EP15839901.4
申请日:2015-09-10
申请人: Shionogi & Co., Ltd.
发明人: KAWASUJI, Takashi , MIKAMIYAMA, Hidenori , SUZUKI, Naoyuki , MASUDA, Koji , SUGIMOTO, Hideki , OKANO, Azusa , YOSHIDA, Miho , SUGIYAMA, Shuichi , ASAHI, Kentarou , KOZONO, Iori , MIYAZAKI, Keisuke , OZASA, Hiroki , MIYAGAWA, Masayoshi
IPC分类号: C07D409/12 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/416 , A61K31/427 , A61K31/428 , A61K31/4436 , A61K31/4525 , A61P31/18 , A61P43/00 , C07D493/04 , C12N9/99
CPC分类号: C07D493/04 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/416 , A61K31/427 , A61K31/428 , A61K31/4436 , A61K31/4525 , A61P31/18 , C07D231/56 , C07D333/72 , C07D409/12 , C07D519/00 , C12N9/99
摘要: The present invention provides useful compounds for HIV protease inhibitor. A compound represented by formula or its pharmaceutically acceptable salt Formula:
wherein ring A is
R 4 is -Y-Z, hydrogen atom, halogen, hydroxy and the like,
R 5 is hydrogen atom, halogen, hydroxy and the like,
R 6 is each independently halogen, hydroxy, carboxy and the like,
ring A may be substituted with said R 6 at any substitutable position(s),
a is an integer of 0 to 7,
ring B is substituted or unsubstituted aromatic carbocyclyl, or substituted or unsubstituted aromatic heterocyclyl,
ring C is substituted or unsubstituted aromatic carbocyclyl, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic heterocyclyl, or substituted or unsubstituted non-aromatic heterocyclyl,
R 1 is -Y-Z, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl and the like,
R 2 and R 3 are each independently -Y-Z or hydrogen atom,
provided that at least one of R 1 , R 2 , R 3 and R 4 is a group represented by formula: -Y-Z,
Y is a bond, or a spacer of any combination selected from the group consisting of -O-, -S-, -NR 7 -, -C(=O)-, -SO-, -SO 2 -, -NR 7 -C(=O)-, -C(=O)-NR 7 -, -NR 7 -C(=O)-NR 7 -, -NR 7 -C(=O)-O-, -SO 2 -NR 7 -, -NR 7 -SO 2 -, substituted or unsubstituted alkylene, substituted or unsubstituted alkenylene, substituted or unsubstituted alkynylene, substituted or unsubstituted aromatic carbocyclediyl, substituted or unsubstituted non-aromatic carbocyclediyl, substituted or unsubstituted aromatic heterocyclediyl and substituted or unsubstituted non-aromatic heterocyclediyl,
R 7 are each independently hydrogen atom, hydroxy, carboxy and the like, and
Z is substituted aromatic carbocyclyl, substituted non-aromatic carbocyclyl, substituted aromatic heterocyclyl or substituted non-aromatic heterocyclyl.摘要翻译: 本发明提供了用于HIV蛋白酶抑制剂的有用化合物。 由式或其药学上可接受的盐表示的化合物或其药学上可接受的盐式:其中环A为R 4为-YZ,氢原子,卤素,羟基等,R 5为氢原子,卤素,羟基等,R 6各自独立地为卤素,羟基 ,羧基等,环A可以在任何可取代的位置被所述R6取代,a是0-7的整数,环B是取代或未取代的芳族碳环基或取代或未取代的芳族杂环基,环C是 取代或未取代的芳族碳环基,取代或未取代的非芳族碳环基,取代或未取代的芳族杂环基或取代或未取代的非芳族杂环基,R1是-YZ,取代或未取代的烷基,取代或未取代的烯基, 例如,R2和R3各自独立地是-YZ或氢原子,条件是R1,R2,R3和R4中的至少一个是由式-YZ表示的基团, Y是键,或选自-O - , - S - , - NR 7 - , - C(= O) - , - SO - , - SO 2 - , - NR 7 -C (= O)-NR 7 - , - NR 7 -C(= O)-NR 7 - , - NR 7 -C(= O)-O - , - SO 2 -NR 7 - ,取代或未取代的亚烷基,取代或未取代的亚烯基,取代或未取代的亚炔基,取代或未取代的芳族碳环基,取代或未取代的非芳族碳环基,取代或未取代的芳族杂环二基和取代或未取代的非芳族杂环二基, ,羟基,羧基等,Z是取代的芳族碳环基,取代的非芳族碳环基,取代的芳族杂环基或取代的非芳族杂环基。
-
-
-
-
-
-
-
-